Lifeward's Exoskeleton Gambit: A Partnership to Scale Human Mobility

HUDSON, MA – August 05, 2026 – Lifeward Ltd., a biomedical innovator known for its neurorehabilitation technologies, has announced a pivotal six-month pilot program with Ottobock Care, one of the nation's premier orthotics and prosthetics patient care organizations. The collaboration is designed to expand U.S. patient access to the ReWalk® 7 Personal Exoskeleton, a device that enables individuals with spinal cord injuries to stand and walk. While the announcement signals a significant step for patient mobility, it also reveals a sophisticated strategy for navigating the complex intersection of advanced technology, clinical infrastructure, and financial scalability.

At its core, the agreement pairs Lifeward’s cutting-edge robotics with Ottobock’s extensive ground game: a network of over 50 patient care clinics staffed by specialists. This move is a calculated response to the primary hurdles that have historically limited the adoption of transformative, yet costly, medical devices—distribution, training, and reimbursement. By leveraging an established clinical partner, Lifeward is aiming to execute a capital-efficient model that could redefine how high-tech medical hardware reaches the people who need it most.

A Strategic Play to Scale Neuromobility

This partnership is far more than a simple distribution deal; it's a cornerstone of Lifeward's evolving corporate strategy. The company, which has been executing a strategic expansion into a diversified biomedical firm, sees this as a way to fortify its foundational neurorehabilitation business. While Lifeward pursues high-value therapeutic platforms like its Protein Oral Delivery (POD™) system for oral insulin, ensuring the commercial success of its flagship products like the ReWalk exoskeleton is paramount for generating stable revenue and maintaining investor confidence.

"Working with Ottobock Care represents an important step in our strategy to make ReWalk available to more people through highly experienced patient care organizations," said Mark Grant, President and CEO of Lifeward, in the official announcement. He emphasized that Ottobock provides the "clinical expertise, regional presence and patient support capabilities needed to accelerate access across the U.S."

The financial context makes this move particularly astute. Lifeward operates in a competitive and capital-intensive market, with rivals like Ekso Bionics also reporting significant growth. For Lifeward, which posted a 28% year-over-year revenue increase in the first quarter of 2024, accelerating the adoption of its personal exoskeleton is critical. The channel partner model allows the company to tap into Ottobock's existing infrastructure, reducing the immense cost and time associated with building out a comparable direct sales and support network nationwide. This pilot is explicitly designed to create a "scalable model that could lead to broader national distribution," a clear signal that Lifeward views this as a long-term solution to commercial growth.

Unlocking Access Amid a Shifting Reimbursement Landscape

The timing of this partnership is no coincidence. It arrives on the heels of a landmark decision by the Centers for Medicare & Medicaid Services (CMS) that fundamentally altered the market for personal exoskeletons. Effective January 1, 2024, CMS established a new national benefit category for personal exoskeletons, ensuring Medicare coverage for medically necessary devices for individuals with spinal cord injuries. This decision dismantled one of the most formidable barriers to access: reimbursement.

For years, patients and manufacturers faced an arduous, case-by-case battle with insurers to cover the six-figure cost of these devices. With a clear Medicare coverage pathway now established—a precedent private insurers often follow—the primary bottleneck has shifted from policy to logistics. The challenge is no longer just if the device will be paid for, but how a patient can be properly evaluated, trained, and supported locally.

This is where the synergy with Ottobock becomes clear. Acquiring and learning to use a device like the ReWalk 7 is an intensive process requiring weeks of specialized physical therapy. Ottobock’s nationwide clinics are positioned to become regional hubs for this critical training and support. By embedding ReWalk expertise within this established network, the partners aim to streamline the patient journey from initial physician referral to confident home and community use. For patients, this could mean less travel, more integrated care, and better long-term outcomes.

"For more than 100 years, the Ottobock family of companies has been committed to helping people achieve greater mobility and independence," noted Kevin Heidenreich, Head of Patient Services at Ottobock Care. He described the ReWalk 7 as a "compelling addition" that aligns with their mission to deliver cutting-edge technology alongside exceptional clinical care. This collaboration promises not only to increase the number of units sold but to fundamentally improve the quality of life for users by ensuring they have the robust clinical support needed to maximize the device's benefits, which can include improved physiological health and profound psychological well-being.

Integrating Robotics into the Continuum of Care

Viewed from a wider angle, the Lifeward-Ottobock pilot exemplifies a maturing of the entire neurorehabilitation technology sector. The era of brilliant inventions languishing in the lab or struggling with market entry is giving way to a more integrated approach where technology developers and clinical care providers form symbiotic relationships. Innovators are recognizing that a groundbreaking device is only as effective as the support system surrounding it.

The global medical exoskeleton market is projected to grow at a staggering compound annual growth rate of over 26%, but this growth is contingent on successful real-world implementation. This partnership serves as a powerful case study in bridging the gap between advanced robotics and the hands-on, human-centric world of patient care. It combines Lifeward’s expertise in AI, robotics, and biomechanics with Ottobock’s century-long experience in fitting devices, managing patient needs, and navigating the healthcare system.

This integrated model is essential for the future of neuromobility. As exoskeletons become smarter—incorporating AI to adapt to a user's gait, or lighter materials for greater comfort—the need for skilled clinicians to manage this technology will only grow. These partnerships create the necessary feedback loop where clinical insights inform future product development, ensuring that the next generation of assistive devices is even more user-friendly, effective, and seamlessly integrated into patients' lives. By building a scalable framework for distribution, training, and reimbursement, Lifeward and Ottobock are not just expanding access to a single product; they are helping to build the foundational infrastructure for the future of robotic rehabilitation.